Objective: To analyze outcomes and predictors of functional survival (personal care home admission and mortality) and hospital readmission in patients aged 80 years who underwent surgical aortic valve replacement (SAVR) in a Manitoba hospital.
Life expectancy of age-and sex-matched Manitobans versus surgical aortic valve replacement recipients aged 80 years.
Central Message
Survival of surgical aortic valve replacement recipients aged 80 years approximates the life expectancy of age-and sex-matched Manitobans.
Perspective
This provincial longitudinal based analysis provides a reference standard for octogenarian patient selection for surgical aortic valve replacement (SAVR). These results can help the SAVR and transcatheter aortic valve implantation team decide which option should provide the best long-term patient outcome and guide the healthcare team and patient-family unit with the informed decision making process. These data can aid prospective healthcare resource planning.
See Editorial Commentary page 1554.
The lifespan in Canada has been increasing since the mid1960s, resulting in a greater number of people living beyond age 80 years. 1, 2 Presently, octogenarians are the population with the fastest growth rate, more than tripling in number over the last 3 decades. 1 The prevalence of calcific aortic stenosis (AS) increases exponentially with age, and recent population studies report that 9.8% of octogenarians have AS. [3] [4] [5] Left untreated, symptomatic AS has a 2-year mortality rate as high as 90%. 6, 7 Consequently, as our population ages, greater numbers of octogenarians are being referred to cardiac surgery for aortic valve disease.
Historically, octogenarians have been considered too high risk for surgical aortic valve replacement (SAVR) because of high rates of mortality, rehospitalization, and poor functional survival (as assessed by personal care home [PCH] admission or mortality). 8 However, over the past 2 decades, advances in intraoperative techniques/ technologies and perioperative care have decreased the risks associated with SAVR, allowing the procedure to be considered in individuals of all ages with or without serious comorbid disease. [9] [10] [11] [12] It has been shown that properly selected octogenarians can have excellent survival rates, functional recovery, and health-related quality of life (HRQoL) after cardiac surgery. 6, 10, 11, 13, 14 Globally, SAVR has been the treatment of choice and reference standard for this patient group, because age itself is no longer an absolute contraindication to surgery. Other perioperative risk factors (eg, urgency of surgery, associated coronary artery bypass grafting [CABG] , New York Heart Association class III-IV, respiratory failure, diabetes, renal failure, ventricular dysfunction) are more important clinical indicators of outcome than age. 10, [14] [15] [16] [17] With the increasing demand for definitive treatment of AS, less-invasive technologies have been developed. Transcatheter aortic valve implantation (TAVI) is increasingly performed in high-risk patients as an alternative to SAVR. 11, 18, 19 In the recent PARTNER 1 trial, 5-year clinical outcomes following TAVI were comparable to those following SAVR in high-risk patients. 20 With improving TAVI technology, clinical experience, and patient selection, indications for the use of TAVI are expected to expand as clinical outcomes improve. 20 Therefore, understanding outcomes of SAVR for comparison with TAVI in octogenarians is relevant for informed shared decision making by the heart team, the patient, and his or her family.
Although numerous studies have described perioperative predictors of long-term mortality after SAVR, there is a lack of information on the rates of rehospitalization and functional survival in older adult patients nearing the Canadian life expectancy (80 years) compared with younger cohorts of active/employed (50-65 years) or retired (66-79 years) groups undergoing SAVR. Addressing this gap in knowledge is important, given that these outcomes are of equal if not greater importance than mortality in older adults with AS. 10, 13, 14 Therefore, the objectives of the present study were to assess outcomes and predictors of mid-term and long-term survival, rehospitalization, and functional survival after SAVR in Manitoba's older adult patients relative to younger cohorts, and secondarily, to provide a context for these outcomes in octogenarians using age-matched population life expectancy data from Statistics Canada.
METHODS

Study Design
This retrospective cohort study was approved by the University of Manitoba's Health Research Ethics Board and Manitoba Health Information and Privacy Committee, and the requirement for individual consent was waived. Between April 1995 and March 2014, 1872 patients, the full cohort of patients 50 years or older inclusive of all surgical urgency status, underwent SAVR with or without concomitant CABG. Patients with infective endocarditis, previous cardiac surgery, and concomitant procedures besides CABG were excluded. Patients were stratified into groups; age 50 to 65 years (n ¼ 425), the active/employed group; age 66 to 79 years (n ¼ 1069), the retired group; and age 80 years (n ¼ 378), a group nearing Canadian life expectancy.
Preoperative, intraoperative, and postoperative data were collected in the Manitoba Adult Cardiac Surgery database initiated in April 1995. This database includes information on patients who underwent surgery at Tables 1 and 2 . The definitions were in accordance with Society of Thoracic Surgeons (STS) guidelines. 21 Before 2009, acute kidney injury (AKI) was defined as a postoperative increase in serum creatinine 176 mmol/L; after 2009, AKI was defined according to STS guidelines as an increase in serum creatinine 1.5 times over the baseline value within the previous 7 days. 22 Prolonged mechanical ventilation was defined as ventilator support for >48 hours. The outcome assessment included 30-day mortality, morbidity, mid-and long-term survival, functional survival (PCH admission and mortality), and hospital 
Statistical Analysis
Baseline patient characteristics were compared among the age groups. Continuous variables were compared using the Kruskal-Wallis test, and categorical variables were compared using the c 2 test. Kaplan-Meier curves were generated for 3 outcomes: survival, functional survival, and freedom from rehospitalization. Follow-up time was calculated based on the patient's surgery date for survival and functional survival outcomes, and based on the patient's hospital discharge date for the freedom from rehospitalization outcome. Only those patients surviving the hospital stay were included in this analysis. Patients were censored based on their last available Manitoba Health, Healthy Living, and Senior health care coverage date. Outcomes of octogenarians after SAVR relative to younger adult patients, survival, and freedom from rehospitalization curves were compared with those of younger age-stratified cohorts using the log-rank test. Octogenarian survival also was compared and plotted against ageand sex-matched survival estimates provided by Statistics Canada for the population of Manitoba. 23 In addition, octogenarian survival was sexstratified and then age-matched to the population of Manitoba in a similar manner. Multivariable Cox proportional hazard models were generated to identify the independent risk factors associated with each of the 3 outcomes in octogenarians and for the full cohort. Cox proportional hazard models also were generated for short-term outcomes by censoring individuals at 1 year following surgery/hospital discharge as opposed to their last available coverage date. All final models were developed via a stepwise selection process. The selection required that a variable have a Score test P value of <.05 for entry into the model and a Wald test P value of <.05 for retention in the model. All variables listed in Tables 1 and 2 except in-hospital mortality were considered in the stepwise selection process and in the primary and secondary outcome rates shown at the bottom of Table 2 . A competing-risks methodology was applied to Kaplan-Meier estimates and Cox proportional hazard models for the rehospitalization outcome. The rehospitalization outcome considered repeating admissions through the use of a conditional Cox proportional hazards model. All analyses was performed using SAS version 9.3 (SAS Institute, Cary, NC).
RESULTS
Demographic Characteristics
The median follow-up time was 6.4 years (interquartile range [IQR], 3.1-10.8 years) for the full cohort (n ¼ 1872) and 5.2 years (IQR, 2.5-8.8 years) for the octogenarians (n ¼ 378). Baseline preoperative patient characteristics for the cohorts are listed in Table 1 . One-fifth (20.2%) of the SAVR recipients were aged 80 years. The proportion of females increased with age (from 31.5% in patients aged 50-65 years to 41.9% in octogenarians). Patients >80 years had higher rates of urgent or emergent procedures, hypertension, congestive heart failure, previous myocardial infarction, transient ischemic attack, peripheral vascular disease, chronic obstructive pulmonary disease, and preoperative atrial fibrillation, as well as lower body surface area and rates of diabetes, dyslipidemia, and smoking. Calcific AS was the most prevalent etiology, with the rate increasing with advancing age. Concomitant CABG procedure (P<.001) and use of a tissue valve also increased with advancing age (P<.001) ( Table 2) .
Clinical 30-Day Outcomes
The 30-day outcomes are presented in Table 2 . The rates of blood transfusion (P <.001) and postoperative AKI (P <.01) increased with advancing age. The mean length of stay in the postoperative intensive care unit (ICU) and in the hospital also increased with age and were 47.2 hours in the ICU (P<.001) and 13.0 days in the hospital (P<.001) in patients aged 80 years. The overall in-hospital mortality also increased in patients aged 80 years (8.5% vs 2.8% in the age 50-65 cohort and 4.4% in the age 66-79 cohort; P <.001).
Survival Outcome
Short-term (30-day), mid-term, and long-term survival were decreased in octogenarians compared with the younger age-stratified cohorts (Figure 1 ). In the patients aged 80 years, median survival was 6.5 years, and 30-day survival was 93.6%, 1-year survival was 83.8%, 5-year survival was 60.8%, and 10-year survival was 19.8%. A comparison of age-and sex-matched survival of octogenarians undergoing SAVR with that of the general Manitoba older adult population shows that after the initial increased perioperative mortality in the SAVR recipients, the longterm survival trajectories are approximately equal ( Figure 2 ). Female survival after SAVR was slightly lower than that of age-matched Manitoba females, whereas male survival closely approximated the expected survival of the general Manitoba older male population. Octogenarian Kaplan-Meier survival rates following cardiac surgery were comparable in the isolated SAVR group and the SAVRþCABG group (P ¼ .24, log-rank test). Survival appeared to improve in the octogenarian patient cohort over time with 30-day, 1-year, and 5-year survival rates of 89.1%, 78.9%, and 54.1%, respectively, in the 1995 to 2004 time period, compared with 96.0%, 86.3%, and 65.1%, respectively, in 2005 to 2014 (P ¼ .02, log-rank test).
Functional Survival
More advanced age was associated with an increasing percentage of patients requiring admission to a PCH (Figure 3) . The median functional survival was 5.8 years for patients aged 80 years, and functional survival of these patients was 93.6% at 30 days, 82.4% at 1 year, 56.5% at 5 years, and 14.5% at 10 years.
Freedom From Rehospitalization
The median time to first rehospitalization decreased with age, and was 2.1 years for patients aged 80 years. In these patients, the 30-day, 1-year, 5-year, and 10-year freedom from rehospitalization rates were 84.9%, 61.5%, 28.4%, and 9.8%, respectively. The freedom from rehospitalization rate was lower in octogenarians compared to the younger age-stratified cohorts (Figure 4) .
Predictors of Adverse Outcome
The significant predictors of survival, functional survival, and rehospitalization in octogenarians at 1 year post-SAVR are presented in Table 3 .
DISCUSSION
This study of patients aged 80 years (n ¼ 378) who underwent SAVR with or without CABG over a 20-year period showed that octogenarians have significantly higher perioperative morbidity and mortality compared with younger patient cohorts. However, once past the initial in-hospital mortality, properly selected octogenarians have excellent long-term survival, with a survival trajectory approaching that of the natural Manitoba life expectancy of older adults. They also have excellent functional survival and freedom from rehospitalization rates compared with younger age-stratified cohorts. Older adults potentially represent a higher-risk group of patients for SAVR owing to baseline comorbidities; however, when assessed preoperatively for risk factors of mortality, functional survival, and rehospitalization, they can have relatively low long-term risk. This study used a large cohort of SAVR patients, 20% of whom were octogenarians. It used detailed documentation of patient information and perioperative outcomes, with up to 10 years of long-term follow up. This study is the first to report outcomes and predictors of survival, poor functional survival, and rehospitalization in Manitoba's octogenarians after SAVR.
The older adult population continues to grow, with the leading cause of death being heart disease. AS is the most prevalent valvular lesion, with a rate that increases with age. 5 Thus, the need to treating AS in older adult patients is expected to increase with the aging population.
Advancing age is associated with longer ICU and hospital lengths of stay and higher rates of rehospitalization and poor functional survival. Our rehospitalization rate in octogenarians was increased relative to younger age stratified cohorts (Figure 4) . Older age was also associated with an increasing rate of admission to a PCH; however, admission to a PCH did not include patients requiring other forms of care, such as adult day services or home care, and thus the number of patients requiring health care services to maintain functional capacity and HRQoL is greater than represented in this study. Thus, SAVR likely will incur greater health resource utilization and potentially lower HRQoL as the population ages.
SAVR has been shown to be safe in properly selected older adult patients, improving survival in many studies. 7, 11, 24, 25 Our in-hospital mortality rate was 8.5% for all SAVR procedures regardless of urgency, inclusive of the combination of SAVR þ CABG, spanning 2 decades (1995-2014). This rate is higher than that reported in the PARTNER1 and PARTNER2 trials, which recruited patients from 2007, a more contemporary octogenarian population. In-hospital mortality and long-term survival rates in this study were slightly lower than but comparable to those in other studies. 10, 12, 13, 15, 16, 24 Octogenarians initially had higher in-hospital and midterm mortality rates compared to the younger cohort ( Figure 1) ; however, their long-term survival rates approximated the trajectory of the sex-and age-matched Manitoban population (Figure 2 ), demonstrating acceptable long-term outcomes even in older adult patients undergoing SAVR. There is still reticence about offering SAVR to older adult patients because of perceived age-related risk, possibly due in part to previous reports identifying age as an independent risk factor for adverse outcomes.
10, 25 Wang and colleagues reported age 80 years as a significant risk factor for long-term mortality (hazard ratio [HR], 4.92; P <.001).
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FIGURE 4. Age-stratified cohort rates of freedom from hospital re-admission up to 10 years post-SAVR. ACQ Similarly, Riera and colleagues found age 70 years to be predictive of mid-term and long-term mortality (HR 2.04; P <.001). 25 However, both studies analyzed patients undergoing all cardiac surgical procedures and used a younger referent group of patients for their statistical analysis than used in our study years by Wang and colleagues and 17-59 years by Riera and colleagues), which could explain this finding of age-related mortality. 10, 25 Our results show that increasing age beyond 60 years was not associated with increased long-term mortality. Other studies have acceptable survival rates, functional outcomes, and HRQoL in properly selected older adult patients. 23, 24 Barring serious comorbid disease, older adult patients had a similar mortality rate as younger patients in many studies. 17, 26, 27 Studies have suggested that adverse outcomes after SAVR are more dependent on the number and severity of relevant predisposing factors and less dependent on chronological age. 11, 17, 24 Older adult patients differ significantly from younger adult patients in baseline comorbidities and cardiac risk factors. Bridges and colleagues demonstrated that patients aged>90 years were less likely to have diabetes, a smoking history, dyslipidemia, and chronic obstructive pulmonary disease, known risk factors for surgical cardiac procedures and decreased life expectancy. 24 They hypothesized that the absence of these risk factors allowed these patients to reach a more advanced age. 24 However, Baleen and colleagues reported higher rates of peripheral vascular disease, congestive heart failure, and previous myocardial infarction in octogenarians compared with younger patients. 26 We found a similar demographic distribution of variables in our study. Bridges and coworkers found significant associations between diabetes, preoperative renal failure, hypertension, and moderate ventricular dysfunction and the risk of mortality in any surgical cardiac procedure in patients aged >90 years. 24 When risk-stratified by the absence of these variables, patient survival rate improved. 24 Therefore, risk-stratifying patients according to predictors of mortality, functional survival, and rehospitalization is essential to prevent these adverse outcomes and accurately select patients for SAVR or other less-invasive procedures. We found associations between preoperative atrial fibrillation and postoperative AKI with increased 1-year mortality in octogenarians. 10, [14] [15] [16] [17] In addition to the predictors of mortality, diabetes was also a significant risk factor for poor 1-year functional survival. The predictors of 1-year survival and 1-year functional survival are almost the same apart from diabetes. In other words, the variables in our databases are not very well suited for prediction, and other variables, such as the presence of dementia, level of activity, and degree of frailty, should be considered as well. Two risk factors, age and female sex, were identified as predictors of rehospitalization at 1 year. Conversely, left ventricular ejection fraction (LVEF) <35%, concomitant CABG, and urgency of operation were not associated with worse outcomes in octogenarians. A possible explanation as to why LVEF <35% was not associated with worse outcomes may be related to the improved LVEF function postoperatively, or, alternatively, this set of patients might not have had other significant risk factors.
More males the females underwent surgery in the present study. The ratio of females to males increased with group age, reflecting the proportional increase in females relative to males in older age groups.
1,2 One study reported lower survival rates for females compared with males of the same age after SAVR, 7 whereas the Canadian Institute for Health Information reported male sex as more predictive of rehospitalization after any surgical procedure (odds ratio, 1.10; 95% confidence interval, 1.07-1.12). 28 Female sex was predictive of rehospitalization at 1 year in octogenarians but it was not a predictor of mortality for octogenarians in our study. Other studies evaluating predictors of ICU readmission after cardiac surgery have found no contribution of sex. 22, 29 In Manitoba, concurrent CABG was performed more frequently in older adult patients undergoing SAVR. Some studies have identified concomitant CABG as a risk factor for increased mortality. 7, 13, 14 Kolh and coworkers found CABG to be a risk factor for early mortality and prolonged ICU stay; however, Melby and colleagues identified concomitant CABG as a protective factor for 30-day and late mortality compared to isolated SAVR. 16 Our study also showed that CABG was protective from 1-year mortality and PCH admission in octogenarians.
Whether concomitant CABG provides a survival benefit in octogenarians is currently unclear. The variation among studies may be related to an unknown and unaccounted- for severity of coronary artery disease that necessitated the bypass. 30 In addition, revascularization with CABG can improve left ventricular function and thus may not be predictive.
TAVI was introduced in Manitoba in September 2012. For the majority of the study period, SAVR was the sole option for patients. Between September 2012 and March 2014, the TAVI program was still being established in Manitoba, with approximately 35 TAVI procedures completed. The future direction for this analysis will be to compare octogenarian patients who underwent a TAVI procedure and those who underwent SAVR once an adequate sample size becomes available. Unfortunately, this analysis is not possible at this time. Based on predictors of survival, rehospitalization, and functional survival, patients aged 80 years without predictors of poor outcome should be referred for surgery, and those with poor predicted outcome based on these risk factors should be referred for TAVI.
The strength of this study lies in the new data from a large provincial population with detailed longitudinal data and predictors of functional survival and readmission. This study has several limitations. First, the study is subject to bias inherent to a retrospective analysis. It is not possible to determine outcomes in patients who were evaluated for SAVR but not offered surgery, and thus selection bias is inherent and cannot be analyzed. Before 2007, data were collected from 2 sites with different perioperative care processes. In 2007, a new dedicated cardiac ICU was initiated, and the cardiac surgery program was consolidated into one site. 31, 32 The effect of changing practice patterns on the outcomes of patients from different eras is unclear. Variables that would have been informative, such as frailty measurements, HRQoL assessments, valve size, and New York Heart Association class, were not reliably collected throughout the study period. The long-term data were deidentified, limiting analysis to aggregate rather than individual patient survival data. Long-term follow-up resulted in patient numbers in the 80-year-old cohort that were too low to allow accurate analysis of predictors of outcome at and beyond 5 years. Standard risk measure scores, like STS or Euroscore II, were not used because data collection varied over the 20-year period. We were unable to compare SAVR results with TAVI results because TAVI was not introduced in our center until 2012, and thus that subsample size was too small. There is a limitation in the interpretation of functional survival data. The term may also imply functional recovery. Individual elderly patients may be admitted to a PCH for various reasons but continue to have a good quality of life, and conversely, some patients who are not admitted to a PCH may have a poor quality of life. This reflects a limitation of the use of administrative databases for long-term outcomes.
CONCLUSIONS
Age 80 years was associated with long-term survival approximating that of the age-matched natural life expectancy, acceptable functional survival, and freedom from rehospitalization at the cost of higher perioperative mortality and morbidity. Predictors of mortality, functional survival, and rehospitalization in older adult patients were preoperative atrial fibrillation, postoperative AKI, diabetes, age, and female sex. Our results provide a reference standard for SAVR outcomes, permitting comparisons with evolving technology, such as TAVI. These provincial results may aid in future decisions regarding longitudinal outcomes after SAVR to be weighed against those of TAVI in selected high-risk patients with comorbidities.
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